Sparx Biopharmaceutical Corp.’s SPX-303, is an anti-LILRB2/PD-L1 bispecific antibody (bsAb) being developed as an anticancer agent.
CHICAGO, April 11, 2024 /PRNewswire/ -- Signifying a monumental step forward in the domain of powered antibody therapies, SparX is thrilled to announce that the first patient has been successfully ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results